Jan Pfeiffenberger

Jan Pfeiffenberger

Auto-generated profile, based on publicly available information

Jan Pfeiffenberger

Internal Medicine IV, Department of Gastroenterology, University Hospital Heidelberg, Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Journal of Hepatology
Verified
Journal Article
Open access
CECornelius Engelmann
Cornelius Engelmann
AHAdam Herber
Adam Herber
AFAnnegret Franke
Annegret Franke
Tony BrunsTony Bruns
Tony Bruns
PRPhilipp Reuken
Philipp Reuken
TBTHOMAS BERG
THOMAS BERG
Based on positive results from small single center studies, granulocyte-colony stimulating factor (G-CSF) is being widely used for the treatment of patients with acute-on-chronic liver failure (ACLF). Herein, we aimed to evaluate the safety and efficacy of G-CSF in patients with ACLF. In this multicenter, prospective, controlled, open-label phase II study, 176 patients with ACLF (EASL-CLIF criteria) were randomized to receive G-CSF (5 μg/kg daily for the first 5 days and every third day thereafter until day 26) plus standard medical therapy (SMT) (n = 88) or SMT alone. The primary efficacy endpoint was 90-day transplant-free survival analyzed by Cox regression modeling. The key secondary endpoints were overall and transplant-free survival after 360 days, the development of ACLF-related complications, and the course of liver function scores during the entire observation period. Patients treated with G-CSF had a 90-day transplant-free survival rate of 34.1% compared to 37.5% in the SMT group (hazard ratio [HR] 1.05; 95% CI 0.711-1.551; p = 0.805). Transplant-free and overall survival at 360 days did not differ between the 2 arms (HR 0.998; 95% CI 0.697-1.430; p = 0.992 and HR 1.058; 95% CI 0.727-1.548; p = 0.768, respectively). G-CSF did not improve liver function scores, the occurrence of infections, or survival in subgroups of patients without infections, with alcohol-related ACLF, or with ACLF defined by the APASL criteria. Sixty-one serious adverse events were reported in the G-CSF+SMT group and 57 were reported in the SMT group. In total, 7 drug-related serious adverse reactions occurred in the G-CSF group. The study was prematurely terminated due to futility after conditional power calculation. In contrast to previous findings, G-CSF had no significant beneficial effect on patients with ACLF in this multicenter controlled trial, which suggests that it should not be used as a standard treatment for ACLF. CLINICALTRIALS. NCT02669680 LAY SUMMARY: Granulocyte-colony stimulating factor was considered as a novel treatment for acute-on-chronic liver failure (ACLF). We performed the first randomized, multicenter, controlled phase II trial, which showed that G-CSF did not improve survival or other clinical endpoints in patients with ACLF. Therefore, G-CSF should not be used to treat liver disease outside clinical studies.

27 April 2023 in Journal of Hepatology
Verified
Journal Article
Closed access
IMIsabelle Mohr
Isabelle Mohr
JPJan Pfeiffenberger
Jan Pfeiffenberger
EEEcem Eker
Ecem Eker
UMUta Merle
Uta Merle
APAurélia Poujois
Aurélia Poujois
KWKarl Heinz Weiss
Karl Heinz Weiss

15 October 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VMVladimir J. Lozanovski, MD
Vladimir J. Lozanovski, MD
LKLarissa T.B. Kerr
Larissa T.B. Kerr
EKElias Khajeh
Elias Khajeh
OGOmid Ghamarnejad
Omid Ghamarnejad
JPJan Pfeiffenberger
Jan Pfeiffenberger
AMArianeb Mehrabi
Arianeb Mehrabi
The major extended donor criteria (maEDC; steatosis >40%, age >65 years, and cold ischemia time >14 h) influence graft and patient outcomes after liver transplantation. Despite organ shortages, maEDC organs are often considered unsuitable for transplantation. We investigated the outcomes of maEDC organ liver transplantation in patients with hepatocellular carcinoma (HCC). Two hundred and sixty-four HCC liver transplant patients were eligible for analysis. Risk factor analysis was performed for early allograft dysfunction; primary nonfunction; 30-day and 90-day graft failure; and 30-day, 90-day, and 1-year patient mortality. One-year graft survival was higher in recipients of no-maEDC grafts. One-year patient survival did not differ between the recipients of no-maEDC and maEDC organs. The univariate and multivariate analyses revealed no association between maEDC grafts and one-year patient mortality. Graft survival differed between the recipients of no-maEDC and maEDC organs after correcting for a laboratory model of end-stage liver disease (labMELD) score with a cut-off value of 20, but patient survival did not. Patient survival did not differ between recipients who did and did not meet the Milan criteria and who received grafts with and without maEDC. Instead of being discarded, maEDC grafts may expand the organ pool for patients with HCC without impairing patient survival or recurrence-free survival.

1 September 2019 in Journal of Gastrointestinal and Liver Diseases
Verified
Journal Article
Open access
PDF file
KFKilian Friedrich
Kilian Friedrich
JKJessica Krempl
Jessica Krempl
SSShigehiko Schamoni
Shigehiko Schamoni
THTheresa Hippchen
Theresa Hippchen
JPJan Pfeiffenberger
Jan Pfeiffenberger
MMMarkus Mieth
Markus Mieth
Background: Multidrug-resistant (MDR) pathogens represent an emerging challenge in end-stage liver disease and in liver transplant recipients. Methods: We evaluated the impact of MDR bacteria upon clinical outcomes in patients with end-stage liver disease (n = 777) at the time of enrollment on the liver transplant (LTx) waiting list, after first LTx (n = 645), and after second LTx (n = 128). Results: Colonization/infection with MDR bacteria was present in 72/777 patients on the waiting list, in 98/645 patients at first LTx, and in 46/128 patients at second LTx. While on the LTx waiting list, the time until first hydropic decompensation (p = 0.021), hepatic encephalopathy (p < 0.001) and hepatorenal syndrome (p < 0.001) was reduced in the presence of MDR bacteria, which remained an independent risk factor of poor survival in multivariate analysis (p < 0.001). Following first and second liver transplant, MDR bacteria were associated with an increased risk of infection-related deaths (first LTx: p < 0.001; second LTx: p = 0.037) and reduced actuarial survival (first LTx: p < 0.001; second LTx: p = 0.046). Conclusions: We showed that MDR pathogens are associated with poor outcomes before, after first and after recurrent LTx.

19 August 2019 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
CWCyrill Wehling
Cyrill Wehling
DHDaniel Hornuss
Daniel Hornuss
PSPasquale Schneider
Pasquale Schneider
CSChristoph Springfeld
Christoph Springfeld
KHKatrin Hoffmann
Katrin Hoffmann
JPJan Pfeiffenberger
Jan Pfeiffenberger

12 September 2019 in Journal of Gastrointestinal and Liver Diseases
Verified
Journal Article
Open access
PDF file
JPJan Pfeiffenberger
Jan Pfeiffenberger
DHDaniel Hornuss
Daniel Hornuss
PHPhilip Houben
Philip Houben
CWCyrill Wehling
Cyrill Wehling
RHRebecca Von Haken
Rebecca Von Haken
KFKilian Friedrich
Kilian Friedrich
Background & Aims: Transient elastography (TE) has routinely been implemented in the diagnosis and assessment of chronic liver disease. Little data are available in the post liver transplant (LTx) setting. Methods: Three months after LTx, we performed TE in 137 liver transplant recipients and investigated its predictive value upon further clinical outcome. The mean follow-up time for clinical outcome was 24 months. Results: Mean TE value was 10.6 kPa (± 6.3 kPa; range 2.8 – 29.9 kPa). There was a significant correlation between TE and aspartate aminotransferase (AST) (p=0.004), gamma-glutamyl transferase (GGT) (p=0.031) and bilirubin (p<0.001) serum levels. In Cox univariate analysis, TE served as a predictor of actuarial survival free of liver transplantation (OR=1.111, 95%CI: 1.051–1.174; p<0.001). In multivariate analysis, TE remained an independent risk factor associated with reduced actuarial survival free of liver transplantation (OR=1.080, 95%CI: 1.001–1.166; p=0.047), along with thrombocytes (OR=0.992, 95%CI: 0.986–0.999; p=0.020) and metabolic co-disease (OR = 0.250, 95%CI: 0.070–0.895; p=0.033). Conclusion: Transient elastography measurement at three months after LTx seems a robust predictor of survival in liver transplant recipients.